International Edition
Latest News
Health

Semaglutide Improves Eating Disorder Symptoms, Body Image in Penn Study

Adults receiving semaglutide 2.4 mg for obesity treatment showed significantly greater reductions in loss-of-control eating, overall eating disorder psychopathology, weight and shape concerns, and body dissatisfaction compared with those receiving placebo, according to a randomized controlled trial published…

Semaglutide Improves Eating Disorder Symptoms, Body Image in Penn Study

Adults receiving semaglutide 2.4 mg for obesity treatment showed significantly greater reductions in loss-of-control eating, overall eating disorder psychopathology, weight and shape concerns, and body dissatisfaction compared with those receiving placebo, according to a randomized controlled trial published Nov. 15 in the International Journal of Eating Disorders.

The study was funded in part by a research grant from the Novo Nordisk NNI Investigator Sponsored Studies Program, with the sponsor playing no role in design, conduct, analysis, or reporting, Newswise reported.

The 60-week trial enrolled 120 adults seeking obesity treatment, randomized in a 3:2 ratio to semaglutide 2.4 mg or placebo. All participants received structured lifestyle intervention including dietary counseling and physical activity guidance. Semaglutide recipients lost an average of 15% of body weight versus 3% in the placebo group, Medical Xpress reported.

Clinicians assessed binge eating and eating disorder psychopathology using the Eating Disorder Examination at baseline and weeks 20, 40, and 60. Questionnaires measured loss of control (Loss of Control Over Eating Scale), drive for thinness and body dissatisfaction (Eating Disorder Inventory and Body Satisfaction Scale), and mood (PHQ-9).

The groups did not differ significantly in binge frequency reductions overall.

Among the 31 participants who reported baseline binge episodes and the 18 with full or subthreshold binge-eating disorder, those receiving semaglutide were more likely to achieve abstinence from binge eating behaviors compared with placebo, Technology Networks reported.

Reliable deteriorations in eating psychopathology, new onset of binge eating, and compensatory behaviors were rare in both groups, and symptom emergence did not appear higher with semaglutide, the abstract notes. However, a small number of participants experienced disordered eating behaviors during the study, highlighting the need for continued monitoring, particularly among individuals with a history of eating disorders, NewsNation reported.

Allison presented the findings at ObesityWeek 2026 in Washington, D.C.

About the author: Health Desk

Health Desk at Archynewsy.